瑞弗利單抗

{{Infobox drug
| type = mab
| image =
| width =
| alt =
| caption =

| mab_type = mab
| source = zu
| target = (PD-1)

| pronounce =
| tradename = Zynyz
| Drugs.com =
| MedlinePlus = a623017
| DailyMedID = Retifanlimab
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category =
| routes_of_administration = 靜脈注射
| class =
| ATC_prefix = L01
| ATC_suffix = FF10
| ATC_supplemental =
| biosimilars =

| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU_comment = ，並於2024年4月獲准於歐盟上市。

參考文獻
外部連結
*